首页 > 期刊杂志 > 正文

A novel next generation sequencing approach to improve sarcoma diagnosis.

McConnell L,Houghton O,Stewart P,Gazdova J,Srivastava S,Kim C,Catherwood M,Strobl A,Flanagan AM,Oniscu A,Kroeze LI,Groenen P,Taniere P,Salto-Tellez M,Gonzalez D
阅读:234 Modern PathologyVolume 33 Issue 7, July 2020:1350-1359 

Abstract

Sarcoma is a rare disease affecting both bone and connective tissue and with over 100 pathologic entities, differential diagnosis can be difficult. Complementing immune-histological diagnosis with current ancillary diagnostic techniques, including FISH and RT-PCR, can lead to inconclusive results in a significant number of cases. We describe here the design and validation of a novel sequencing tool to improve sarcoma diagnosis. A NGS DNA capture panel containing probes for 87 fusion genes and 7 genes with frequent copy number changes was designed and optimized. A cohort of 113 DNA samples extracted from soft-tissue and bone sarcoma FFPE material with clinical FISH and/or RT-PCR results positive for either a translocation or gene amplification was used for validation of the NGS method. Sarcoma-specific translocations or gene amplifications were confirmed in 110 out of 113 cases using FISH and/or RT-PCR as gold-standard. MDM2/CDK4 amplification and a total of 25 distinct fusion genes were identified in this cohort of patients using the NGS approach. Overall, the sensitivity of the NGS panel is 97% with a specificity of 100 and 0% failure rate. Targeted NGS appears to be a feasible and cost-effective approach to improve sarcoma subtype diagnosis with the ability to screen for a wide range of genetic aberrations in one test.

摘要

full text

我要评论

0条评论